Chemotherapy-induced menopause

Being told that your cancer treatment might also end your fertility and trigger menopause — on top of everything else a cancer diagnosis brings — is a lot to take in at once. Here's what the evidence actually says about risk, reversibility, and what's worth asking before treatment begins.

How likely is this, really?

It depends heavily on which drugs you're receiving and your age. A systematic review of 45 studies covering 5,607 female survivors of childhood and young adult cancer found that amenorrhoea (absent periods) rates after chemotherapy ranged from 0% to 83%, depending on the specific treatment regimen. Some figures from that review:

• Patients on MVPP protocols (used for some lymphomas): 39–79% developed amenorrhoea
• Breast cancer survivors on cyclophosphamide-containing regimens: 40–80% developed amenorrhoea
• The strongest risk factors identified were alkylating agents (specifically procarbazine and busulfan) and older age at the time of treatment

The review's own authors are candid that all the studies they reviewed had methodological limitations, and call for better long-term tracking of cancer survivors. That's worth knowing: the exact numbers for your specific regimen may be better discussed directly with your oncologist, who can factor in your specific drugs, doses, and age.

Temporary or permanent?

This genuinely varies. Younger women and those on lower-risk regimens are more likely to see their periods and ovarian function return in the months to a couple of years after finishing treatment. Older age and higher-risk regimens (especially alkylating agents) make permanent ovarian failure more likely. Because no one can predict this with certainty for an individual in advance, two things matter most: discussing fertility preservation before treatment starts if that's relevant to you, and not assuming periods are gone for good just because they stop during treatment.

Fertility preservation: a before-treatment conversation

If future fertility matters to you, this is a conversation to have before chemotherapy begins, ideally with a referral to a fertility specialist alongside your oncology team. Standard options discussed at this stage typically include egg or embryo freezing and, in some cases, ovarian tissue preservation — which option (if any) fits depends on your specific cancer, treatment timeline, and how much time is available before treatment must start. This is time-sensitive, so raise it as early as possible rather than waiting.

Managing symptoms if menopause does occur

If chemotherapy does trigger menopause symptoms — hot flashes, night sweats, vaginal dryness — management needs to be coordinated with your oncology team, since systemic hormone therapy is often not an option depending on your cancer type. See our dedicated guide on menopause after breast cancer for evidence-based non-hormonal options, many of which apply regardless of cancer type, and check any specific non-hormonal option against our does it work? evidence directory before trying it, since some supplements can interact with cancer treatment. If your periods don't return and you're under 40, see our guide on premature ovarian insufficiency for what longer-term bone and heart protection involves.

Questions to take to your oncology team

Build a printable version in our treatment conversation builder: